Evidence map›Paper›PMID 42814138›Full record

ArticleArchives of toxicology2026

Applicability of NAMs to support a read-across based hazard assessment workflow for systemic toxicity: a conazole case study.

Barira Islam, Jenny Irwan, Lukas Wijaya, Bas Ter Braak, Amer Jamalpoor, Tamara Meijer, Clemence Budin, Tjalf de Boer, Shu Liu, Marlene Wedler and 22 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Barira IslamMID3, Certara UK, 1 Concourse Way, Level 2-Acero, Sheffield, S1 2BJ, United Kingdom. barira.islam@certara.com.ORCID http://orcid.org/0000-0001-5882-6903
Jenny IrwanFraunhofer Institute for Toxicology and Experimental Medicine, Chemical Safety and Toxicology, Munich, Germany.
Lukas WijayaDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Bas Ter BraakToxys B.V, Leiden Bio Science Park, Oegstgeest, 2342 DH, the Netherlands.
Amer JamalpoorToxys B.V, Leiden Bio Science Park, Oegstgeest, 2342 DH, the Netherlands.ORCID http://orcid.org/0000-0001-5630-4159
Tamara MeijerToxys B.V, Leiden Bio Science Park, Oegstgeest, 2342 DH, the Netherlands.ORCID http://orcid.org/0000-0002-4623-3753
Clemence BudinBioDetection Systems, Science Park 406, Amsterdam, 1098 XH, the Netherlands.
Tjalf de BoerBioDetection Systems, Science Park 406, Amsterdam, 1098 XH, the Netherlands.
Shu LiuGerman Centre for the Protection of Laboratory Animals (Bf3R) and Experimental Toxicology, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.ORCID http://orcid.org/0000-0002-2904-0271
Marlene WedlerGerman Centre for the Protection of Laboratory Animals (Bf3R) and Experimental Toxicology, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.ORCID http://orcid.org/0009-0004-4702-1324
Baiba GukalovaNational Institute of Research and Innovation, Riga, Latvia.
Edgars LiepinsNational Institute of Research and Innovation, Riga, Latvia.
Jaione TelleriaMedBioInformatics Solutions, Rambla de Cataluña 14, 7º, 1ª, Barcelona, 08007, Spain.ORCID http://orcid.org/0009-0008-2630-5298
Laura FurlongMedBioInformatics Solutions, Rambla de Cataluña 14, 7º, 1ª, Barcelona, 08007, Spain.ORCID http://orcid.org/0000-0002-9383-528X
Guillame OllitraultUniversité Paris Cité, INSERM U1133, CNRS UMR 8251, Paris, France.ORCID http://orcid.org/0009-0008-5119-9044
Sam DavidseDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Tessa M S HagensDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Sibel BahtiriDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Olivier TaboureauUniversité Paris Cité, INSERM U1133, CNRS UMR 8251, Paris, France.
Nadine DreserDepartment of in vitro toxicology and biomedicine, Faculty of Sciences, University of Konstanz, Konstanz, Germany.
Philip Marx-StoeltingGerman Centre for the Protection of Laboratory Animals (Bf3R) and Experimental Toxicology, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.ORCID http://orcid.org/0000-0002-6487-2153
Annika JärvinenDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Per ArturssonDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-3708-7395
Patrik LundquistDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-7458-7882
Kathrin BotheCrop Science, Bayer AG, Monheim am Rhein, Germany.ORCID http://orcid.org/0000-0001-6470-8882
Hennicke KampGerman Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Marcel LeistDepartment of in vitro toxicology and biomedicine, Faculty of Sciences, University of Konstanz, Konstanz, Germany.ORCID http://orcid.org/0000-0002-3778-8693
Bob van de WaterDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Andrew WhiteUnilever Safety Environmental and Regulatory Science, Bedfordshire, UK.
Mirjam LuijtenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.ORCID http://orcid.org/0000-0002-5277-1443
Iain GardnerMID3, Certara UK, 1 Concourse Way, Level 2-Acero, Sheffield, S1 2BJ, United Kingdom.
Sylvia E EscherFraunhofer Institute for Toxicology and Experimental Medicine, Chemical Safety and Toxicology, Munich, Germany.

Funding

European Union's Horizon 2020 RISK-HUNTER, grant agreement No 964537Horizon 2020 681002
6 · The paper itself

Abstract

This work explores the applicability of new approach methodologies (NAMs) using a read-across approach to predict systemic toxicity with liver as the critical target organ, and derive a point of departurefor the target compound (TC) difenoconazole. Eight conazoles were used as source compounds (SCs), alongside metabolites hydroxyitraconazole and 1,2,4-triazole. The case study was structured according to the Alternative Safety Profiling Algorithm (ASPA) workflow developed within the RISK-HUNT3R project. Hierarchical clustering using chemical fingerprints identified similarity of different SCs to the TC, supporting their inclusion in the read-across analysis. A broad screening panel of NAMs, including nuclear receptor reporter assays, ToxProfiler, Cell Painting PLUS, transcriptomics in primary human hepatocytes and H295R steroidogenesis assays, was used to characterize biological activity of the TC and SCs and to substantiate the structure-based read-across. In a first prediction round, the nearest neighbour quantitative read-across approach (based on allometrically-scaled human lowest-observed-adverse-effect levels (LOAELs) of the SC) was used to predict 6.57 mg/kg/day as the LOAEL of the TC. This closely aligned with the in vivo-based value of 4.88 mg/kg/day. In a second approach, data from NAMs were used to predict human equivalent dose (HED), and the respective LOAELs of SC and TC, based on physiologically based kinetic modelling with quantitative in vitro to in vivo extrapolation. The HED derived from NAMs was approximately ten-fold lower than the LOAELs from traditional approaches. This case study illustrates suitable (ASPA-guided) approaches as well as the toxicological applicability of a NAM-based read-across assessment to obtain safe/conservative estimates of toxicity.

Identifiers

PMID42814138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.